Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$8.51 - $14.26 $5,352 - $8,969
-629 Reduced 3.78%
16,000 $151,000
Q4 2022

Feb 14, 2023

BUY
$7.05 - $14.41 $117,234 - $239,623
16,629 New
16,629 $177,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $28.2M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.